

Pegasparaginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

NHS
University Hospitals
Birmingham
NHS Foundation Trust

MRN: Ward/Unit:

Name: DOB: Consultant:

Address:

NHS No:

Recorded by Date

Height Weight BSA Date

Allergies:

Nature of allergy:

Hepatitis B serology:

Treatment intent: Palliative

Cycle number:

Funding status: N/A

Emetogenic potential: Moderately emetogenic

Extravasation classification: Oxaliplatin—irritant.

Gemcitabine and Peg-asparaginase—non-vesicant.

Hepatitis B serology:

Treatment intent: Palliative

Cycle number:

To be given every 21 days. First 2 courses prior to radiotherapy then 2-4 courses after radiotherapy.

Tick if EBV PCR has been checked

Day No. Date	DRUG or ELECTROLYTE	CALCULATION	DOSE	IV FLUIDS	VOL. MLS.	ROUTE/FLOW RATE	SPECIAL DIRECTIONS/ ADMINISTRATION DETAILS	DRUG	TIME	Pharmacy
	Akynezo	One capsule	Oral				1 hour prior to chemotherapy	Sig.		
	Famotidine	20mg	Oral				30min - 1h pre Pegasparaginase			
	Paracetamol	1000mg	Oral				30min - 1h pre Pegasparaginase			
	Chlorphenamine	10mg					IV bolus 30min pre- pegasparaginase			
	Dexamethasone	8mg					IV bolus 30min pre- pegasparaginase			
1	PEGASPARAGINASE	2000 units/m ²	Intramuscular							
				Sodium Chloride 0.9%	50ml	IV over 5 mins	IV infusion to flush line			
	GEMCITABINE	1000mg/m ²		Sodium Chloride 0.9%	250ml	IV infusion over 30 mins				
	OXALIPLATIN	130mg/m ²		Glucose 5%	50ml	IV over 5 mins	IV infusion to flush line			
				Glucose 5%	250ml	IV infusion over 2 hours				
				Glucose 5%	50ml	IV over 5 mins	IV infusion to flush line			

Prescriber sig: Name: Date:

Pharmacist initial sig: Name: Date:

Pegasparaginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

Written by: Steve Hill
Checked by (Pharmacist)
RH
20/6/24Authorised by: Prem Mahendra
P. Mahendra
Clinical Nurse Specialist:
*K Stockton*Reference: Kilzhang et al. Am J Hematol. 2021;96:1481-
1490.**NHS**Authorised by: Prem Mahendra
*P. Mahendra*Written by: Steve Hill
Checked by (Pharmacist)
RH
20/6/24Authorised by: Prem Mahendra
P. Mahendra
Clinical Nurse Specialist:
*K Stockton*Reference: Kilzhang et al. Am J Hematol. 2021;96:1481-
1490.**NHS**Authorised by: Prem Mahendra
*P. Mahendra*Written by: Steve Hill
Checked by (Pharmacist)
RH
20/6/24Authorised by: Prem Mahendra
P. Mahendra
Clinical Nurse Specialist:
*K Stockton*Reference: Kilzhang et al. Am J Hematol. 2021;96:1481-
1490.**NHS**

MRN:
Name:
DOB:
Address:
NHS No:

Hb	Na+	Alb	Height
WBC	K+	AIKP	Weight
Plt	Urea	ALT	BSA
Neuts	Cr	Bili	Date
PT	GFR	Amylase	Allergies:
APTT	Ca	Glucose	<input type="text"/>
Fibrinogen	Mg		Nature of allergy:

Recorded by Date

To be given every 21 days. First 2 courses prior to radiotherapy then 2-4 courses after radiotherapy.

Tick if EBV PCR has been checked

Day No. Date	DRUG or ELECTROLYTE	CALCULATION	DOSE	IV FLUIDS	VOL. MLS.	ROUTE/FLOW RATE	SPECIAL DIRECTIONS/ ADMINISTRATION DE- TAILS	DRUG ADMINISTRATION	TIME	Pharmacy
8	GEMCITABINE	1000mg/m ²	10mg	Sodium Chloride 0.9%	50ml	IV over 5 mins	IV bolus			
				Sodium Chloride 0.9%	250ml	IV infusion over 30 mins	IV infusion to flush line			
				Sodium Chloride 0.9%	50ml	IV over 5 mins	IV infusion to flush line			

Medications to be prescribed on PICs

Supportive medication

Anti-emetics

- Metoclopramide 10mg TDS PO PRN
- Dexamethasone 4mg BD PO for 3 days starting on day 1
- Co-trimoxazole 480mg BD M/W/F
- Filgrastim as required

Prescriber sig: Name: Date:

Pharmacist initial sig: Name: Date:

Pegasparaginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

Proceed rules

FBC valid within 96 hours of day 1, with 48 hours of day 8. (U+Es/LFTs within 7 days of day 1):

Drug	Neuts ($\times 10^9/\text{L}$)	Platelets ($\times 10^9/\text{L}$)	Dose Modification	Renal	Hepatic
Gemcitabine and Oxaliplatin	≥ 1.0	≥ 75	100% dose	Oxaliplatin: CrCl $\geq 30 \text{ mL/min}$ — No dose adjustment needed	Oxaliplatin : N/A
Day 1	≥ 1.0	< 75	Delay 1 week If platelets > 75 resume at 100% If platelets 50–75 resume at 100% dose with platelet support If platelets < 50 resume at 75%	Gemcitabine: CrCl $< 30 \text{ mL/min}$ — discuss with consultant, consider 50% dose	Gemcitabine: Bilirubin $\geq 27 \mu\text{mol/L}$ — Consider starting at 80% dose
	< 1.0	≥ 75	Delay 1 week If neuts > 1.0 resume at 100% with GCSF support		
	< 1.0	< 75	Delay 1 week If neuts > 1.0 platelets > 75 resume at 100% with GCSF support If platelets 50–75 resume at 100% dose with platelet support If platelets < 50 resume at 75%	Gemcitabine: N/A	Gemcitabine: Bilirubin $\geq 27 \mu\text{mol/L}$ — Consider starting at 80% dose
Gemcitabine	≥ 1.0	≥ 75	100% dose		
Day 8	< 1.0	< 75	Contact prescriber		
Pegasparaginase	≥ 1.0	≥ 75	100% dose	N/A	No dose adjustments but can cause liver toxicity

If amylase $> 3 \times \text{ULN}$, fibrinogen $< 0.5 \text{ g/L}$, or new onset significant LFT derangement contact prescriber

Prescriber sig: Name: Date:

Pharmacist initial sig: Name: Date:

Rota code: HROTA423	Issue date: June 2024	Written by: Steve Hill <i>[Signature]</i>	Authorised by: Prem Mahendra <i>[Signature]</i>	Page: 4 of 4
Version no. 1.0	Valid until: Next review	Checked by (Pharmacist) <i>[Signature]</i> 2026 20/6/24	Clinical Nurse Specialist: <i>[Signature]</i> K Stockton	Reference: Zhang et al. Am J Hematol. 2021;96:1481-1490.

Pegasparaginase, Gemcitabine, Oxaliplatin (P-GemOx). Natural Killer Cell Lymphoma.

Other Information

Pegasparaginase:

For Pegasparaginase, monitor BP and vitals and visual inspection of injection site before and after injection, observe for 1 hour

Fresh frozen plasma not recommended

Oxaliplatin:

If the neurosensory toxicity is NCI-CTC grade 1–2 and lasts less than 7 days administer full dose oxaliplatin. If the toxicity is NCI-CTC grade 2 and persists for more than 7 days reduce the oxaliplatin dose to 97.5mg/m². Oxaliplatin should be discontinued for neuro-sensory toxicities NCI-CTC grade 3 or above.

If NCI-CTC grade 3-4 diarrhoea or stomatitis recurs despite appropriate reduction in the dose the oxaliplatin dose should be reduced to 97.5mg/m².